Healionics

Executive Summary

Healionics, a Seattle-based medical device company founded in 2005, is advancing its proprietary STAR biomaterial platform to address critical unmet needs in vascular access for dialysis patients. The STAR material is designed to promote rapid biointegration and tissue regeneration, potentially reducing complications such as infection, thrombosis, and stenosis that plague current synthetic grafts. With over 400,000 end-stage renal disease patients in the U.S. relying on hemodialysis, a durable and infection-resistant access solution represents a multibillion-dollar market opportunity. Healionics’ technology has shown promise in preclinical and early clinical studies, demonstrating improved healing and patency rates. The company is now focused on advancing its lead product, the STAR arteriovenous graft, through clinical development. If successful, Healionics could disrupt the $1.5 billion vascular access market, offering a safer alternative to both synthetic grafts and native fistulas. However, the path to commercialization involves rigorous FDA review and proven long-term outcomes. The company’s strong IP position and experienced management team bolster its prospects, though the lack of disclosed funding rounds suggests a lean operation. With mounting clinical evidence, Healionics is well-positioned to attract strategic partnerships or acquisition interest from larger medtech players.

Upcoming Catalysts (preview)

• Q3 2026Interim Data Readout from Pivotal Clinical Trial of STAR Graft70% success
• Q4 2026FDA Pre-Submission Meeting for STAR Graft Approval Pathway90% success
• Q2 2026Strategic Partnership with Major Dialysis Provider or Device Company50% success